Biotech IPOs Deliver 55% Weighted Average Return This Year, Outperforming AI Sector
N.R. Finch
U.S. biotech IPOs have delivered a 55% weighted average return in 2026, while the ten largest U.S. IPOs — mostly AI-linked — fell a weighted average of 6.3%. An M&A wave and strong drug pipelines are driving the divergence.
55% return vs. an overall loss — how wide is the gap?
Biotech and pharma IPOs posted a 55% weighted average return this year. The broader U.S. IPO market, excluding blank-check vehicles, averaged a 4.4% loss.
The ten largest U.S. IPOs of 2026 fell a weighted average of 6.3% — most were AI-related.
This means → The market is not seeing a broad IPO recovery. One sector is surging alone while the rest tread water or slide.
Where is the money coming from? How three mega-deals fed the IPO pipeline.
Three deals of $10 billion or more landed in the past month: AbbVie acquiring Apogee Therapeutics, GSK acquiring Nuvalent, and Vertex Pharmaceuticals acquiring Crinetics Pharmaceuticals.
In plain terms = Big pharma buys smaller companies, the sellers' investors cash out, and that cash flows straight into the next wave of IPOs.
Seth Rubin, global head of equity capital markets at Stifel Financial, said: "Some of the world's largest fund families are reallocating capital into healthcare."
How much have IPO volume and proceeds grown?
The number of biotech IPOs in 2026 has already surpassed last year's full-year total of 8 deals. Total proceeds topped $5 billion — roughly triple last year's figure.
Parabilis Medicines raised $770.6 million last month, the largest biotech IPO on record.
This reflects a step-change in both scale and confidence — not just a few extra deals.
Which stocks have gained the most?
Veradermics, a hair-loss drug maker, is up more than 500% since its February listing — the best-performing U.S. IPO of 2026 across all sectors.
Hemab Therapeutics Holdings, focused on blood disorders, has doubled since its May debut.
This means → The top performers are not platform-scale companies. They are single-disease specialists — the market is paying up for pipelines close to a clinical endpoint.
Who is lining up to list next?
At least six biotech companies filed for IPOs this month.
Among them is Scribe Therapeutics, built on CRISPR gene-editing technology — a tool that can precisely rewrite DNA. It plans to price in late July to early August.
Jack Bannister, senior managing director of equity capital markets at Leerink Partners, called this "the healthiest biotech IPO market we've seen in a long time."
Can this run last? Where is the risk?
Bannister noted that persistently high interest rates would pressure biotech valuations.
But he added: "Right now the sector is trading independently of rates and in the opposite direction from AI."
In plain terms = Biotech is running on its own logic for now, but if rates stay elevated, the valuation ceiling will eventually come down — the second half of the year is the key test.
Content is for reference only, not financial advice.